Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 5, 2026
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trialKan Yonemori, Shin Nishio, Shiro Suzuki, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 23, 2025
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial executionFernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial designIgnace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial designIgnace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.Gynecologic Oncology|February 14, 2026
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO- E/GOG-3041/ENGOT-EN10 trialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.Lancet (London, England)|February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trialDavid M Gershenson, Austin Miller, William E Brady, et al.Therapeutic Advances in Medical Oncology|September 30, 2024
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Annika Auranen, Matthew A Powell, Vladyslav Sukhin, et al.Gynecologic Oncology|February 9, 2023
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancerThomas J Herzog, Sandro Pignata, Sharad A Ghamande, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Normal Risk Ovarian Screening Study: 21-Year UpdateChae Young Han, Karen H Lu, Gwen Corrigan, et al.Gynecologic Oncology|January 24, 2020
Low-grade serous ovarian cancer: State of the scienceBrian Slomovitz, Charlie Gourley, Mark S Carey, et al.Pageof 5